ExpreS2ion will participate in key investor events in September 2021
ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in September. These include events hosted by LSX Leaders, Aktiespararna, Økonomisk Ugebrev and Dansk Aktionærforening.
Meet and ask questions directly to our CEO, Bent U. Frandsen, and other members of management and the Board, at these investor events. To participate, please register via the links below. Additional information and updates can be found on the Meet Us page of the ExpreS2ion website.
LSX Leaders Nordic Congress, September 6-17
An opportunity for investors and potential partners to meet CEO Bent Frandsen, CFO Keith Alexander, and Board Member Jakob Knudsen, in 1-on-1 virtual meetings. Read more and register now.
Aktiespararna Aktiedagen Digitalt, September 7, 11:00 CET
CEO Bent Frandsen will make a live presentation viewable on Aktiespararna's YouTube channel.
Økonomisk Ugebrev Life Science Investor Conference (in Danish), September 22, 13:30 – 18:00 CET
Symbion Fruebjergvej, 3 Fruebjergvej, 2100 København
Come see CEO Bent Frandsen's latest investor presentation. Sign up here.
Event hosted by Dansk Aktionærforening (in Danish), September 27, 17:30 – 21:00 CET
Kolding Uddannelsescenter, Ågade 27, 6000 Kolding, Denmark
CEO Bent Frandsen will present ExpreS2ion to investors and potential investors. Sign up here.
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
Keith Alexander, CFO
Telephone: +45 5131 8147
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel capsid VLP based vaccines through its 34% owned joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com.